STAT+: A U.K. trade group scolds Novo again — this time for remarks made by its CEO
Once again, Novo Nordisk has been admonished by a U.K. trade group for violating voluntary…
Category: STAT+
STAT+: AI app claiming to diagnose STIs from penis pictures shut down after FTC scrutiny
The company that claimed its AI model could identify sexually transmitted infections from a single…
STAT+: Big Health gets FDA nod for its digital therapy for insomnia
Digital Therapeutics developer Big Health this week received Food and Drug Administration clearance for SleepioRx,…
.jpg)
STAT+: A strong start for Madrigal’s MASH drug launch
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Pharmalittle: We’re reading about a Purdue overdose-reversal device, a discontinued Merck trial, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: AI drug developers Recursion, Exscientia to merge
Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia,…
STAT+: Eli Lilly boosts 2024 revenue guidance by $3 billion on Mounjaro, Zepbound sales
Eli Lilly raised its full-year revenue guidance by $3 billion, driven by massive sales of…
STAT+: Orlando Health, a $6 billion Florida powerhouse, is expanding into Alabama
As for-profit Tenet Healthcare slims its hospital portfolio, it found an unlikely buyer for its…
STAT+: Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England
LONDON — Patients in England with a rare blood disorder will now be able to…
STAT+: Medicare finalizes reimbursement rule for breakthrough medical devices
The Centers for Medicare and Medicaid Services has finalized its rule easing reimbursement for medical…
STAT+: CVS removes top Aetna leader as higher medical costs eat further into profits
CVS Health continued to pay out more than it expected for the medical claims of…
STAT+: The race to build better CRISPR delivery vehicles is heating up
If the first CRISPR decade was marked by a mad dash to evolve, engineer, and…
STAT+: FDA scolds Bristol Myers over a misleading website for a cancer treatment
The U.S. Food and Drug Administration has scolded Bristol Myers Squibb for making false and…
STAT+: Pharmalittle: We’re reading about Roche plans for Flatiron, underwhelming Novo Nordisk earnings, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data
Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug…
STAT+: How UnitedHealth turned a questionable artery-screening program into a gold mine
The nation’s largest health care company pressed thousands of its clinicians to use a thinly…
STAT+: Supply issues weigh on Novo Nordisk as drugmaker stumbles with quarterly report
LONDON — An underwhelming earnings report and ongoing questions about increasing competition in the booming…
STAT+: Pharmalittle: We’re reading about a canceled Roche trial, low VC biotech funding, and more
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: Biotech mogul Arie Belldegrun extends empire with launch of $600 million credit firm
Arie Belldegrun has yet another job: He wants to be your lender. On Tuesday, Belledegrun…
STAT+: ‘Jerking families around’: Canceled Roche rare disease trial devastates parents, angers researchers
Roche, the Swiss pharmaceutical giant, earlier this year abruptly cancelled an international clinical trial of…
STAT+: Biotech VCs are pacing for another record-low year of fundraising amid glimpses of recovery
Life science venture capital firms are pacing for another record-low year of fundraising, potentially hindering…
STAT+: Jeff Shuren stabilized the FDA’s medical devices center, winning over industry but not all patients
Retirements from the Food and Drug Administration are hardly shocking, especially in the wake of…
STAT+: Lawmakers cast doubt on expert panel studying alcohol for 2025 dietary guidelines
Alcohol policy researchers are fuming over a letter sent by members of Congress last month,…
STAT+: BioMarin to restrict sales of hemophilia gene therapy, seeking to overcome slow sales
Struggling to find new patients, BioMarin Pharmaceuticals on Monday said it would restrict sales of…
STAT+: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs
Frustrated by the lack of access to expensive weight loss drugs, North Carolina officials are…
STAT+: Pharmalittle: We’re reading about MDMA trials, weight loss drug availability, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Medicare scrambles to keep prescription drug plan premiums stable ahead of elections
WASHINGTON — Medicare officials are offering private insurers big subsidies to keep premiums for prescription-drug…
STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more
Good morning, and happy Friday. This is Jonathan Wosen, West Coast biotech and life sciences…
STAT+: 23andMe board rejects co-founder Anne Wojcicki’s offer to take company private
A special committee of the board of directors of 23andMe rejected an offer from the…
STAT+: UnitedHealth and HCA clash over hospital chain’s rates in ‘battle of the giants’
Contract disputes between hospitals and health plans have become routine, but they tend to be…
.jpg)
STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer
LONDON — U.S. regulators have authorized a cutting-edge treatment relying on T cells for a…
STAT+: Private equity firms to acquire health care billing and payments firm R1 in $8.9 billion deal
R1 RCM is finally getting taken off the public markets, ending a months-long saga between…
STAT+: On Andrew Left and the government’s fraud case
I love the Summer Olympics. Every four years I transform into a huge fan of…
STAT+: Jim Wilson, gene therapy pioneer, departs Penn to set up new companies
Jim Wilson, a leading gene therapy researcher who has persisted through the field’s ups and…
STAT+: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more
Greetings from London, with STAT reporter Andrew Joseph here filling in for Ed for the…
STAT+: With new data, RegenxBio advances plan for Duchenne gene therapy
Regenxbio said Thursday that its experimental gene therapy for Duchenne muscular dystrophy was administered to…
STAT+: Eli Lilly’s obesity drug Zepbound shows benefits in heart failure patients
Eli Lilly’s obesity drug Zepbound cut the risk of complications and improved symptoms in patients…
STAT+: 23andMe co-founder Anne Wojcicki files to take company private
A trust controlled by 23andMe co-founder Anne Wojcicki has formally filed to take the genetic…
STAT+: Pharmalittle: We’re watching GLP-1 drug data in Alzheimer’s, a flu shot push for livestock workers, and more
Good morning, folks! The Dean of Pharmalittle University, Ed Silverman, is out on vacation. I…
STAT+: Mount Sinai mounted aggressive campaign to stifle debate over revelations about its controversial brain research
Mount Sinai, a leading hospital network in New York City, has mounted an extraordinary behind-the-scenes…
STAT+: 7 key people who could shape Trump’s health care policy
WASHINGTON — A second Trump administration would bring a new wave of health policy officials…
STAT+: Wells Fargo faces class action lawsuit over workers’ high drug costs
Former employees sued Wells Fargo on Tuesday, alleging the banking giant violated federal law by…
STAT+: Eisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new data
Patients with early Alzheimer’s disease treated with a medication developed by Eisai and Biogen for…
STAT+: Merck shares fall as sales of HPV vaccine drop in China
Shares of Merck fell 9% Tuesday after the company reported that in the second quarter,…
STAT+: Picking apart health care lobbying, from Grindr to Lipton Tea
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: We’re reading about the U.K. nixing coverage for a cancer drug, sharing bird flu vaccine data, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Older GLP-1 drug may help protect brains of Alzheimer’s patients, early study suggests
A new study suggests that an older GLP-1 drug may help protect the brains of…
STAT+: Health care’s ‘Pepsi challenge’: Doctors’ offices are testing AI tools in head-to-head pilots
The “Pepsi challenge” of health care, as one health system executive put it, is on….
STAT+: How to tell if Biden drove a hard bargain on drug prices
WASHINGTON — The deadline for announcing how much Medicare lowered drug prices in the first…
STAT+: Dental AI startup raises $30 million, including from Mark Zuckerberg’s dad
As the AI race in dentistry grows more heated, a startup called Perceptive is aiming…